2015-2019 年美国新药和生物制剂临床试验中的种族和民族代表性。
Racial and Ethnic Representation in US Clinical Trials of New Drugs and Biologics, 2015-2019.
机构信息
Office of the Commissioner, US Food and Drug Administration, Silver Spring, Maryland.
Center for Biologic Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
出版信息
JAMA. 2021 Dec 7;326(21):2201-2203. doi: 10.1001/jama.2021.16680.
Abstract
This study reviews the participation of racial and ethnic populations at US sites in 2015-2019 to understand the extent to which US trial participation represents the diversity of the US population.
摘要
本研究回顾了 2015-2019 年美国研究点中种族和民族人群的参与情况，以了解美国试验参与在多大程度上代表了美国人口的多样性。
相似文献
1
Racial and Ethnic Representation in US Clinical Trials of New Drugs and Biologics, 2015-2019.2015-2019 年美国新药和生物制剂临床试验中的种族和民族代表性。
JAMA. 2021 Dec 7;326(21):2201-2203. doi: 10.1001/jama.2021.16680.
2
Racial and Ethnic Diversity in Studies Funded Under the Best Pharmaceuticals for Children Act.《最佳儿童药物法案》资助研究中的种族和民族多样性。
Pediatrics. 2021 May;147(5). doi: 10.1542/peds.2020-042903. Epub 2021 Apr 12.
3
Diversity in clinical trials in Europe and the USA: a review of a pharmaceutical company's data collection, reporting, and interpretation of race and ethnicity.欧洲和美国临床试验中的多样性：对一家制药公司种族和族裔数据收集、报告及解读情况的综述
Ann Oncol. 2023 Dec;34(12):1194-1197. doi: 10.1016/j.annonc.2023.09.3107. Epub 2023 Sep 27.
4
Racial and Ethnic Representation of Participants in US Clinical Trials of New Drugs and Biologics.美国新药和生物制品临床试验参与者的种族和族裔代表性
JAMA. 2022 Mar 8;327(10):985. doi: 10.1001/jama.2022.0875.
5
Racial and Ethnic Representation of Participants in US Clinical Trials of New Drugs and Biologics-Reply.美国新药和生物制品临床试验参与者的种族和族裔代表性——回复
JAMA. 2022 Mar 8;327(10):985. doi: 10.1001/jama.2022.0878.
6
An Evaluation of Novel Oncology Approvals with a PMR/C for Assessing Data in Racial and Ethnic Populations Underrepresented in Premarket Clinical Trials.评估具有 PMR/C 的新型肿瘤学批准，以评估在上市前临床试验中代表性不足的种族和族裔人群的数据。
Clin Cancer Res. 2024 Aug 15;30(16):3388-3394. doi: 10.1158/1078-0432.CCR-24-0852.
7
Classification of race and ethnicity: implications for public health.种族和族裔分类：对公共卫生的影响。
Annu Rev Public Health. 2003;24:83-110. doi: 10.1146/annurev.publhealth.24.100901.140927. Epub 2002 Oct 23.
8
Racial, Ethnic, and Gender Representation in Leadership Positions at National Cancer Institute-Designated Cancer Centers.国家癌症研究所指定癌症中心领导层中的种族、族裔和性别代表性。
JAMA Netw Open. 2021 Jun 1;4(6):e2112807. doi: 10.1001/jamanetworkopen.2021.12807.
9
Association of the COVID-19 Pandemic With Estimated Life Expectancy by Race/Ethnicity in the United States, 2020.2020 年美国因新冠大流行导致的按种族/族裔估计的预期寿命变化的相关研究
JAMA Netw Open. 2021 Jun 1;4(6):e2114520. doi: 10.1001/jamanetworkopen.2021.14520.
10
Trends in Racial and Ethnic Disparities in COVID-19 Hospitalizations, by Region - United States, March-December 2020.2020 年 3 月至 12 月美国按地区划分的 COVID-19 住院患者的种族和民族差异趋势。
MMWR Morb Mortal Wkly Rep. 2021 Apr 16;70(15):560-565. doi: 10.15585/mmwr.mm7015e2.
引用本文的文献
1
Reporting of Sociodemographic and Clinical Characteristics in US-Based Randomized Clinical Trials of Deprescribing Interventions for Older Adults.美国针对老年人减药干预的随机临床试验中社会人口学和临床特征的报告
Drugs Aging. 2025 Jul 5. doi: 10.1007/s40266-025-01226-0.
2
Representation of Women, Older Adults, and Racial and Ethnic Minoritized Patients in Pivotal Trials for US Food and Drug Administration Novel Oncology Therapeutic Approvals, 2012-2021: Bright Spot Trials and Trends Over Time.2012年至2021年美国食品药品监督管理局新型肿瘤治疗药物批准的关键试验中女性、老年人以及少数族裔患者的代表性：亮点试验及随时间的趋势
JCO Oncol Pract. 2025 Jun 10:OP2400563. doi: 10.1200/OP-24-00563.
3
Auricular Point Acupressure for Older Adults with Chronic Low Back Pain: A Randomized Controlled Trial.耳穴按压治疗老年慢性下腰痛：一项随机对照试验。
Pain Med. 2025 Mar 27. doi: 10.1093/pm/pnaf035.
4
Navigating the Path to Inclusion: Understanding Barriers and Facilitators to Clinical Trial Participation Among Chinese Older Adults in the United States with Multimorbidity.探索融入之路：了解美国患有多种疾病的中国老年人参与临床试验的障碍与促进因素
J Gen Intern Med. 2025 Feb;40(2):393-401. doi: 10.1007/s11606-024-09162-2. Epub 2024 Nov 4.
5
A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis.一项关于司库奇尤单抗在不同种族和族裔中重度银屑病患者群体中的疗效和安全性的描述性事后分析。
Dermatol Ther (Heidelb). 2024 Oct;14(10):2877-2887. doi: 10.1007/s13555-024-01268-z. Epub 2024 Oct 2.
6
Variations in racial and ethnic groups' trust in researchers associated with willingness to participate in research.不同种族和族裔群体对研究人员的信任度差异与参与研究的意愿相关。
Humanit Soc Sci Commun. 2023;10. doi: 10.1057/s41599-023-01960-z. Epub 2023 Aug 2.
7
A Multidisciplinary Assessment of ChatGPT's Knowledge of Amyloidosis: Observational Study.对ChatGPT关于淀粉样变性知识的多学科评估：观察性研究。
JMIR Cardio. 2024 Apr 19;8:e53421. doi: 10.2196/53421.
8
Racial and ethnic diversity in global neuroscience clinical trials.全球神经科学临床试验中的种族和民族多样性。
Contemp Clin Trials Commun. 2024 Jan 4;37:101255. doi: 10.1016/j.conctc.2024.101255. eCollection 2024 Feb.
9
Allyship to Advance Diversity, Equity, and Inclusion in Otolaryngology: What We Can All Do.耳鼻喉科促进多元化、公平性与包容性的盟友关系：我们都能做些什么。
Curr Otorhinolaryngol Rep. 2023 Sep;11(3):201-214. doi: 10.1007/s40136-023-00467-0. Epub 2023 Jul 4.
10
British South Asian ancestry participants views of pharmacogenomics clinical implementation and research: a thematic analysis.英国南亚裔参与者对药物基因组学临床实施和研究的看法：一项主题分析。
Pharmacogenomics J. 2023 Nov;23(6):185-194. doi: 10.1038/s41397-023-00317-8. Epub 2023 Nov 1.
本文引用的文献
1
Demographic diversity of participants in Pfizer sponsored clinical trials in the United States.辉瑞赞助的美国临床试验参与者的人口统计学多样性。
Contemp Clin Trials. 2021 Jul;106:106421. doi: 10.1016/j.cct.2021.106421. Epub 2021 Apr 30.
2
Inclusion, analysis, and reporting of sex and race/ethnicity in clinical trials: have we made progress?临床试验中纳入、分析和报告性别及种族/民族：我们是否取得了进展？
J Womens Health (Larchmt). 2011 Mar;20(3):315-20. doi: 10.1089/jwh.2010.2469. Epub 2011 Feb 25.
Zotero 插件